Enterprise Value
-37.39M
Cash
185.5M
Avg Qtr Burn
-24.7M
Short % of Float
0.43%
Insider Ownership
0.42%
Institutional Own.
78.37%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
SGT-001 (Microdystrophin Gene Transfer) Details Genetic disorder, Muscle degeneration, Muscle weakness | Phase 1/2 Update |